Examples of amyloid-negative (left) and amyloid-positive (right) positron emission tomography (PET) scans. In this figure, the amyloid-PET ligand [18F]AZD4694 is shown. The hotter colours indicate more amyloid-PET tracer binding, and colder colours indicate low amyloid-PET tracer binding. The prototypical amyloid-positive PET pattern is of elevated amyloid in the brain’s posterior cingulate cortex, prefrontal cortex, as well as lateral parietal and temporal cortices. These regions display minimal tracer uptake in the amyloid-negative case (left), who has low binding across the whole cerebral cortex. Finally, it is important to note that amyloid-PET tracers have some binding to white matter, which explains the small amounts of hotter colours in the amyloid-negative case.
More information on amyloid-PET visual reads can be found in Johnson KA, Minoshima S, Bohnen NI, et al. “Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association”. Alzheimers Dement. 2013;54(3):476-490
Related content
Advances in blood biomarkers are transforming the diagnosis and prognosis of Alzheimer’s disease, helping to assess pathology, disease progression, and co-existing pathologies.
Overview of how blood-based biomarkers may support screening, diagnosis, staging, prognosis, and treatment decisions across the Alzheimer’s disease continuum.
Overview of a plasma biomarker testing pathway for symptomatic Alzheimer’s disease, using p-tau217 and eMTBR-tau243 to guide diagnostic assessment and identify underlying pathology.